Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies
Open Access

Phase II Trial of Capecitabine Plus Bevacizumab for Elderly Patients With Metastatic Colorectal Cancer: OGSG 1102

TOSHIFUMI YAMAGUCHI, MOTOKI YOSHIDA, KOICHI TAIRA, SHINYA TOKUNAGA, TAKESHI KATO, MASATO NAKAMURA, NAOTOSHI SUGIMOTO, SOICHI FUMITA, MASAYOSHI YASUI, YASUHIRO MIYAKE, HISATO KAWAKAMI, YUKINORI KUROKAWA, TOSHIO SHIMOKAWA and TAROH SATOH
In Vivo May 2025, 39 (3) 1505-1513; DOI: https://doi.org/10.21873/invivo.13950
TOSHIFUMI YAMAGUCHI
1Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: toshifumi.yamaguchi{at}ompu.ac.jp
MOTOKI YOSHIDA
1Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOICHI TAIRA
2Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINYA TOKUNAGA
2Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKESHI KATO
3Department of Surgery, Kansai Rosai Hospital, Amagasaki, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASATO NAKAMURA
4Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NAOTOSHI SUGIMOTO
5Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SOICHI FUMITA
6Department of Medical Oncology, Kishiwada City Hospital, Kishiwada, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAYOSHI YASUI
7Department of Surgery, Kaizuka City Hospital, Kaizuka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUHIRO MIYAKE
8Department of Surgery, Nishinomiya Municipal Central Hospital, Nishinomiya, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HISATO KAWAKAMI
9Department of Medical Oncology, Kindai University Faculty of Medicine, Higashi-osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKINORI KUROKAWA
10Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOSHIO SHIMOKAWA
11Department of Medical Data Science, Graduate School of Medicine, Wakayama Medical University, Wakayama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAROH SATOH
10Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 39 no. 3 1505-1513
DOI 
https://doi.org/10.21873/invivo.13950
PMID 
40295031

Published By 
International Institute of Anticancer Research
Print ISSN 
0258-851X
Online ISSN 
1791-7549
History 
  • Received December 28, 2024
  • Revision received January 22, 2025
  • Accepted January 24, 2025
  • Published online April 28, 2025.

Copyright & License 
Copyright © 2025 The Author(s). Published by the International Institute of Anticancer Research. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

Author Information

  1. TOSHIFUMI YAMAGUCHI1⇑,
  2. MOTOKI YOSHIDA1,
  3. KOICHI TAIRA2,
  4. SHINYA TOKUNAGA2,
  5. TAKESHI KATO3,
  6. MASATO NAKAMURA4,
  7. NAOTOSHI SUGIMOTO5,
  8. SOICHI FUMITA6,
  9. MASAYOSHI YASUI7,
  10. YASUHIRO MIYAKE8,
  11. HISATO KAWAKAMI9,
  12. YUKINORI KUROKAWA10,
  13. TOSHIO SHIMOKAWA11 and
  14. TAROH SATOH10
  1. 1Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Osaka, Japan;
  2. 2Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan;
  3. 3Department of Surgery, Kansai Rosai Hospital, Amagasaki, Japan;
  4. 4Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan;
  5. 5Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan;
  6. 6Department of Medical Oncology, Kishiwada City Hospital, Kishiwada, Japan;
  7. 7Department of Surgery, Kaizuka City Hospital, Kaizuka, Japan;
  8. 8Department of Surgery, Nishinomiya Municipal Central Hospital, Nishinomiya, Japan;
  9. 9Department of Medical Oncology, Kindai University Faculty of Medicine, Higashi-osaka, Japan;
  10. 10Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan;
  11. 11Department of Medical Data Science, Graduate School of Medicine, Wakayama Medical University, Wakayama, Japan
  1. Toshifumi Yamaguchi, MD, Ph.D., 2-7, Daigaku-machi, Takatsuki, Osaka 569-8686, Japan, Tel: +81 726831221, Fax: +81 726846778, e-mail: toshifumi.yamaguchi{at}ompu.ac.jp
View Full Text

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

In Vivo: 39 (3)
In Vivo
Vol. 39, Issue 3
May-June 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Phase II Trial of Capecitabine Plus Bevacizumab for Elderly Patients With Metastatic Colorectal Cancer: OGSG 1102
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
5 + 9 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Phase II Trial of Capecitabine Plus Bevacizumab for Elderly Patients With Metastatic Colorectal Cancer: OGSG 1102
TOSHIFUMI YAMAGUCHI, MOTOKI YOSHIDA, KOICHI TAIRA, SHINYA TOKUNAGA, TAKESHI KATO, MASATO NAKAMURA, NAOTOSHI SUGIMOTO, SOICHI FUMITA, MASAYOSHI YASUI, YASUHIRO MIYAKE, HISATO KAWAKAMI, YUKINORI KUROKAWA, TOSHIO SHIMOKAWA, TAROH SATOH
In Vivo May 2025, 39 (3) 1505-1513; DOI: 10.21873/invivo.13950

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Phase II Trial of Capecitabine Plus Bevacizumab for Elderly Patients With Metastatic Colorectal Cancer: OGSG 1102
TOSHIFUMI YAMAGUCHI, MOTOKI YOSHIDA, KOICHI TAIRA, SHINYA TOKUNAGA, TAKESHI KATO, MASATO NAKAMURA, NAOTOSHI SUGIMOTO, SOICHI FUMITA, MASAYOSHI YASUI, YASUHIRO MIYAKE, HISATO KAWAKAMI, YUKINORI KUROKAWA, TOSHIO SHIMOKAWA, TAROH SATOH
In Vivo May 2025, 39 (3) 1505-1513; DOI: 10.21873/invivo.13950
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Polymorphisms of FGFR Pathway-related Factors and Capecitabine-induced Hand-foot Syndrome in Japanese Patients With Colorectal Cancer
  • Google Scholar

More in this TOC Section

  • Association Between Dipeptidyl Peptidase-4 Inhibitor Use and Acute Kidney Injury in Patients With Diabetes Mellitus: A Disproportionality Analysis Based on the FAERS
  • Expression Patterns of T-cell immunoreceptor With Ig and ITIM domains (TIGIT) in Classical Hodgkin Lymphoma: A Clinicopathological Study
  • Older Age and Outcomes of Intravesical Bacillus Calmette-Guérin for Non-muscle-invasive Bladder Cancer
Show more Clinical Studies

Keywords

  • colorectal cancer
  • elderly
  • capecitabine plus bevacizumab
In Vivo

© 2026 In Vivo

Powered by HighWire